Artal Group S.A. Pro Qr Therapeutics N.V. Transaction History

Artal Group S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$4.14 - $9.22 $4.95 Million - $11 Million	-1,196,218 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$4.79 - $6.3 $301,573 - $396,641	-62,959 Reduced 5.0%	1,196,218 $5.73 Million
Q2 2020 Aug 14, 2020	SELL	$4.5 - $6.53 $183,703 - $266,574	-40,823 Reduced 3.14%	1,259,177 $7.66 Million
Q2 2019 Aug 09, 2019	SELL	$9.1 - $15.55 $910,000 - $1.56 Million	-100,000 Reduced 7.14%	1,300,000 $11.8 Million
Q4 2018 Feb 11, 2019	BUY	$15.25 - $22.4 $1.53 Million - $2.24 Million	100,000 Added 7.69%	1,400,000 $22.1 Million
Q3 2018 Nov 09, 2018	SELL	$6.45 - $21.6 $1.29 Million - $4.32 Million	-200,000 Reduced 13.33%	1,300,000 $25.2 Million
Q2 2018 Aug 10, 2018	SELL	$2.95 - $7.45 $1.18 Million - $2.98 Million	-400,000 Reduced 21.05%	1,500,000 $11 Million
Q4 2017 Feb 09, 2018	BUY	$2.8 - $4.8 $1.12 Million - $1.92 Million	400,000 Added 26.67%	1,900,000 $6.13 Million
Q3 2017 Nov 08, 2017	BUY	$4.35 - $6.45 $6.52 Million - $9.68 Million	1,500,000	1,500,000 $7.28 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $184M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.